:
Meglitinides are a group of oral hypoglycemic medications currently approved for the treatment of type 2
diabetes mellitus (T2DM). Two meglitinide molecules, Repaglinide and Nateglinide,are presently in use. Repaglinide is
preferred because of its superior glycemic efficacy.They have modest efficacy with a mean decrement of glycosylated
haemoglobin (HbA1c) ranging between -0.2 to -1.50% with individual therapy. Additional HbA1c reduction can occur
with combination therapy with other oral hypoglycemics. This class of drugs is effective in controlling postprandial
hyperglycemia with minimal risk of hypoglycemia.It is also useful in patients in with variable meal timings, especially in
the elderly, and in patients with renal failure. There are is a dearth of long-term studies on meglitinides to assess
cardiovascular outcomes or mortality in T2DM,although the Nateglinide and Valsartan in Impaired Glucose
ToleranceOutcomes Research (NAVIGATOR) study showed no difference between Nateglinide and placebo with regard
to the core composite cardiovascular outcomes. Based on a PubMed literature search using key words: ‘meglitinides’,
‘repaglinide’, ‘nateglinide’, ‘HbA1c’, ‘glycated haemoglobin’, ‘cardiovascular safety’, ‘cardiovascular events’,
‘cardiovascular outcome trials’, ‘type 2 diabetes mellitus’ and heart failure, and combining the search terms using
Boolean operators ‘AND’, ‘OR’ and ‘NOT’ as needed we compiled current evidence for use of these oral hypoglycemic
agents in clinical use. This article is an attempt to review the efficacy and cardiovascular (CV) safety of Meglitinides to
help clinicians to use this class of oral hypoglycaemic agents prudently.
198 Primary care use of SGLT2 inhibitors in patients with type 2 diabetes mellitus and cardiovascular disease – are we missing a trick?
